Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Vodafone Group’s (NASDAQ: VOD) Mixed Analyst Sentiment Reflects Market Uncertainty

Shares of Vodafone Group Public Limited (NASDAQ:VOD) carry an average rating of “Hold” according to seven analysts currently tracking the stock. The consensus breaks down into one “Sell,” three “Hold,” two “Buy,” and one “Strong Buy” recommendation, signaling a divergence in views on the …

Team Kalkine | 16 June 2025

Super Group (NYSE: SGHC) Receives Consensus “Buy” Recommendation from Analysts

Shares of Super Group (NYSE: SGHC) have earned a consensus rating of “Buy” from the six brokerage firms currently covering the stock. Of these, five analysts issued a buy rating, while one analyst gave a strong buy recommendation. The average 12-month price target across …

Team Kalkine | 16 June 2025

BetMGM Raises FY2025 Revenue Guidance to USD 2.6 billion, Ups EBITDA Forecast

BetMGM LLCis a U.S.-based sports betting and iGaming operator jointly owned by MGM Resorts International (NYSE:MGM) and Entain plc (LSE:ENT). The company operates through a partnership structure, combining exclusive access to MGM Resorts’ U.S.-based land-based and online gaming assets with Entain’s U.S.-licensed technology platform. …

Team Kalkine | 15 June 2025

WISeKey Welcomes Rolf Gobet to Advisory Role

WISeKey International Holding Ltd (NASDAQ:WKEY)is a Swiss-based cybersecurity and digital identity company that operates through a network of specialized subsidiaries. Its portfolio includes SEALSQ Corp which develops semiconductors, public key infrastructure (PKI), and post-quantum cryptography solutions. WISeKey SA, which provides Root of Trust and …

Team Kalkine | 15 June 2025

Prothena Reports Roche Advancing Prasinezumab to Phase III for Parkinson’s Disease

Prothena Corporation plc (NASDAQ:PRTA)is a clinical-stage biotechnology company focused on developing therapies targeting protein dysregulation in neurodegenerative and rare peripheral amyloid diseases. Its pipeline includes investigational therapies for conditions such as ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease, and other disorders involving misfolded proteins. The …

Team Kalkine | 15 June 2025

Roku Partners with Amazon Ads to Expand Authenticated CTV Reach in U.S.

Roku, Inc. (NASDAQ:ROKU)headquartered in San Jose, California, is a streaming platform and device maker that sells Roku-branded TVs and smart home products in the U.S., licenses its technology globally to OEMs, and operates The Roku Channel, a widely used app offering free and premium …

Team Kalkine | 15 June 2025

Global Markets Update: Middle East Tensions Shake Equities, Lift Oil and Gold

Index Update:U.S. markets saw a risk-off tone as Israel’s strike on Iran heightened geopolitical tensions, weighing on airline and megacap tech stocks, while boosting oil and defense shares. Despite the volatility, major indexes are still on course for modest weekly gains, with the S&P …

Team Kalkine | 13 June 2025

Archer Aviation (NYSE: ACHR) Raises USD 850 Million to Advance eVTOL Integration and Global Expansion

Archer Aviation Inc. (NYSE: ACHR)is a U.S.-based developer of electric vertical takeoff and landing aircraft focused on short-haul urban air mobility. The company is working on the development and certification of its Midnight aircraft and is engaged in partnerships across regulatory, infrastructure, and commercial …

Team Kalkine | 13 June 2025

AIRO Group Holdings Announces USD 60M IPO for NASDAQ Listing

AIRO Group Holdings, Inc.a company focused on aerospace, defense, and advanced mobility technologies, announced the pricing of its initial public offering (IPO) of 6,000,000 shares of common stock at a price of USD 10.00 per share. The IPO is expected to raise approximately USD …

Team Kalkine | 13 June 2025

BioArctic (Nasdaq Stockholm: BIOA B) Proceeds With Higher Doses in Parkinson’s, MSA Phase 2a Trial

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)based in Sweden, focuses on research and development of therapies aimed at neurodegenerative diseases. The company previously partnered with Eisai on the development of Leqembi® (lecanemab), an approved treatment for early Alzheimer’s disease. Beyond Alzheimer’s, BioArctic is pursuing …

Team Kalkine | 13 June 2025